Bioavailability Endpoints

Bioavailability Endpoints is a pharmacokinetic measurement serving as a quantitative indicator of the rate and extent to which an active drug ingredient or metabolite becomes available at the site of action, specifically used as a primary metric in bioequivalence studies to assess equivalence between formulations.

23

Publications

2K

Citations

141

Authors

53

Institutions

Publications per year

2017–2026

3

Authors

141

  1. JW
    J. W. ERDMANJR

    University of Illinois Urbana-Champaign, United States

    1 publications · 44 citations

    1

    h-index

  2. JJ
    Juan J. Martínez Medina

    National University of the Chaco Austral, Argentina

    1 publications · 61 citations

    1

    h-index

  3. WY
    Wenge Yang

    Ningbo University, China

    1 publications · 13 citations

    1

    h-index

  4. WE
    William E. Anderson

    Carolinas Medical Center, United States

    1 publications · 18 citations

    1

    h-index

  5. EM
    Elsa Martínez-Ferri

    Andalusian Institute of Agricultural and Fisheries Research and Training, Spain

    1 publications · 89 citations

    1

    h-index

1–5 of 141

Venues

  1. Clinical Pharmacology & Therapeutics

    CPT · 2 publications · 29 citations

    2

    h-index

  2. American Journal of Veterinary Research

    AJVR · 1 publications · 20 citations

    1

    h-index

  3. Food Chemistry

    1 publications · 89 citations

    1

    h-index

  4. PubMed

    Repository · 1 publications · 23 citations

    1

    h-index

  5. Environmental Toxicology and Chemistry

    1 publications · 47 citations

    1

    h-index

1–5